GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 06:22:51 2024-05-24 am EDT 5-day change 1st Jan Change
1,785 GBX +0.41% Intraday chart for GSK plc +0.66% +23.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rate outlook weighs on equities Our Logo
GSK: successful verdict in Zantac case CF
GSK: to present its advances in oncology at ASCO CF
FTSE 100 falls; retail sales plunge in April AN
GSK celebrates Illinois jury verdict in Valadez case AN
GSK to Continue Vigorous Defense of Zantac Cancer Claims After Recent US Victory MT
UK retail sales fall amid wet April; Co-Op Bank deal AN
GSK Says Illinois Jury Finds Heartburn Drug Zantac Not Liable for Plaintiff's Cancer DJ
GSK, Boehringer Ingelheim Bag Win in Zantac Cancer Case US Trial MT
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Sector Update: Health Care MT
GSK's Zantac Didn't Cause Woman's Cancer, Chicago Jury Verdict Says MT
GSK's Zantac Cleared in Chicago Jury Trial for Alleged Colon Cancer Link MT
GSK's Zantac Cleared in Chicago Jury Trial for Alleged Colon Cancer Link MT
GSK on Zantac Litigation Says Will Continue To "Vigorously Defend" Itself Against All Claims RE
GSK - VERDICT CONSISTENT WITH SCIENTIFIC CONSENSUS THAT THERE IS… RE
GSK: NEXT ZANTAC TRIAL DUE TO START IN ILLINOIS DISMISSED… RE
GSK: JURY IN VALADEZ CASE IN ILLINOIS STATE COURT FINDS GSK NOT… RE
GSK: STATEMENT: ZANTAC (RANITIDINE) LITIGATION - VALADEZ AND WIL… RE
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
News Highlights : Top Company News of the Day - Wednesday at 1 AM ET DJ
GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies MT
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update DJ
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.78 GBP
Average target price
20.32 GBP
Spread / Average Target
+14.30%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix